Who to call at Aquestive Therapeutics, Inc., and when
Fundz watches for the moments Aquestive Therapeutics, Inc. starts buying, and tells you who to reach.
- An alert the day Aquestive Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Aquestive Therapeutics, Inc., from your own LinkedIn network
Aquestive Therapeutics, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
aquestive.comAI Executive Summary
AI-powered analysis of 8-K filing content
Aquestive Therapeutics appointed Richard J. Daly as a Class I director effective October 14, 2026, with his term expiring at the 2028 Annual Meeting. This board expansion reflects the company's strategic effort to strengthen governance and leadership oversight.
Key Takeaways
Richard J. Daly elected as Class I director, effective October 14, 2026
Director term expires at the Company's 2028 Annual Meeting of Stockholders
2 more takeaways
Filing Overview
What This Means
Aquestive Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.